

U.S. EPA ORD, CSS Research Program Board of Scientific Counselors Subcommittee NAMS Research and Development, Session D: System-specific Models and Approaches February 2-3, 2021

Neurovascular Unit Modeling and Blood Brain Barrier Function

Thomas B. Knudsen, PhD Developmental Systems Biologist

Center for Computational Toxicology and Exposure


Research Triangle Park NC 27711

knudsen.thomas@epa.gov ORCID 0000-0002-5036-596x

DISCLAIMER: The views expressed are those of the presenters and do not reflect Agency policy.

Fetal Brain Barriers

The Neurovascular Unit (NVU) is a relatively recent concept describing the relationship between neuronal and vascular compartments, particularly for two key processes:



- main driver of functional hyperemia, matching local blood supply to neuronal demand via glutamate (stimulates release of vasoactive signals from astrocytes and pericytes).
- development and regulation of the cerebral blood-brain barrier (BBB) that is fundamental as a selective transport barrier to maintain an optimal environment for brain function.


BBB pathophysiology

• Evidence linking BBB dysfunction with prenatal/antenatal pathophysiological states:



- defective brain transport of leptin (obesity)
- reduced CNS insulin (baroreceptor deficiency in pregnancy)
- o microglial activation and neuroinflammation (Zika-microcephaly, FIRS)
- o GLUT1 deficiency syndrome (epilepsy, learning disabilities)
- SL75A (LAT1) dysfunction (autism)
- SL16A2 (MCT8) deficiency (altered thyroid delivery and neurological impairment)
- DNT hypoxia, metal toxicity, pesticide toxicity, ...
- OECD Test No. 424: Neurotoxicity Study in Rodents does not directly evaluate BBB function but can be influenced by a breakdown in the function in the various cell types.
- We know that chemicals interact with the BBB, but to what extent do chemicals of interest disrupt its development and function?

BBB microvasculature: *late fetal to adult lifestages*



Researchgate.net

Endothelial cells: continuous tight junctions, no fenestrations, limited transcytosis.

<u>**Pericytes</u>**: produce a basement membrane continuous with that produced by the endothelial microvasculature.</u>

<u>Astrocytes</u>: processes (end-feet) interact directly with the basement membrane; appear after formation of the BBB.

Microglia: resident macrophages of the brain, are of hematopoietic origin in the early embryonic yolk sac.


• Microglia orchestrate neurovascular patterning through local signaling; however, when activated they can invoke a local neuroinflammatory response.


BBB phylogeny

DOI: 10.1002/bdr2.1180				
REVIEW ARTICLE	WILEY Birth Defects Society			
Blood-brain barrier development: Systems modeling and predictive toxicology				
Katerine S. Saili ¹ 💿 🕴 Todd J. Zurlinde Aymeric Silvin ³ 🕴 Nancy C. Baker ⁴ 🖻 Thomas B. Knudsen ¹ 🕲	en ¹			

Key BBB transporters are conserved


Species	GLUT1	P-gly	SLC7A5
Human	100	100	100
Chimpanzee	99.7	99.5	99.6
House mouse	97.3	87.1	81
Zebrafish	81.3	64.8	77.7
Australian ghostshark	82.7	65.7	72.7
Amphioxus	38	54.5	61.6
Waterflea	46.1	48.5	45.4
House fly	50	41.5	48.5
Arctic lamprey	64.4		
Giant Pacific octopus			






BBB ontogeny

E8.25-E8.5



E9.25-E9.5






- Different components emerge and mature at different stages of prenatal development.
- Commences with angiogenic sprouting from the perineural vascular plexus (PNVP).
- ECs + PCs invade the embryonic neural epithelium on E9-10 (mouse) and GD 26 (human).
- Circulating microglia from the yolk sac colonize the neuroepithelium → resident macrophages of the brain.
- BBB properties (tight junctions, GLUT1) and barrier function (TEER) evident by E11 and increases to birth.

Microglia are required to establish BBB/microvasculature




• promote vascular patterning and BBB barrier development in the embryonic forebrain.



*EPA-A*STAR collaboration with A Silvin, F Ginhoux – A*STAR/SIgN*

Hypothesis: *'microglial sensing' is a key event in BBB developmental toxicity*

BBB Knowledgebase sifter



513 records → main subject (MeSH) on BBB in an article

115 DNT chemicals → main subject (MeSH) in an article annotated for development/embryology AND neurological effects

82 chemicals \rightarrow 5 with DNT effects on BBB BPA, 5FU, Pb, paraquat, retinoic acid

Int J Dev Neurosci. 2004 Feb;22(1):31-7.

Mosquito repellent (pyrethroid-based) induced dysfunction of blood-brain barrier permeability in developing brain.

Sinha C1, Agrawal AK, Islam F, Seth K, Chaturvedi RK, Shukla S, Seth PK.

Author information

Abstract


Pub

Pyrethroid-based mosquito repellents (MR) are commonly used to protect humans against mosquito vector. New born babies and children are often exposed to pyrethroids for long periods by the use of liquid vaporizers. Occupational and experimental studies indicate that pyrethroids can cause clinical, biochemical and neurological changes, and that exposure to pyrethroids during organogenesis and early developmental period is especially harmful. The neurotoxicity caused by MR has aroused concern among public regarding their use. In the present study, the effect of exposure of rat pups during early developmental stages to a pyrethroid-based MR (allethrin, 3.6% w/v, 8h per day through inhalation) on blood-brain barrier (BBB) permeability was investigated. Sodium fluororescein (SF) and Evan's blue (EB) were used as micromolecular and macromolecular tracers, respectively. Exposure during prenatal (gestation days 1-20), postnatal (PND1-30) and perinatal (gestation days 1-20 + PND1-30) periods showed significant increase in the brain uptake index (BUI) of SF by 54% (P < 0.01), 70% (P < 0.01), 79% (P < 0.01), respectively. This increase persisted (68%, P < 0.01) even 1 week after withdrawal of exposure (as assessed on PND37). EB did not exhibit significant change in BBB permeability in any of the group. The results suggest that MR inhalation during early prenatal/postnatal/perinatal life may have adverse effects on infants leading to central nervous system (CNS) abnormalities, if a mechanism operates in humans similar to that in rat pups.

development.


HTS profiling of angiogenic-neurogenic chemical bioactivity






Zurlinden et al. 2020, Reprod Toxicol

- HTS data generated on up to 58 reference chemicals across 18 diverse cell-based angiogenic and neurogenic features.
- ToxPi bioactivity signatures used to train a logistic regression literature model to annotate clusters with PubMed MeSH.
- Chemical-specific pairwise mutual information score predicts NVU developmental hazard potential for advanced modeling.






BBB systems model for predictive toxicology


Saili et al. 2017, Birth Defects Res


Advanced Modeling: neovascularization of the neural tube



CCTE, work in progress


Executing a simulated concentration-response








- Progressive bioactivity affects microglial-endothelial interaction (reduced tortuosity → deficiency of SVZ).
- Quantitative microvascular 'cybermorphs' predicts an AC50 for Mancozeb disruption at 0.5 μ M.




Checking the prediction: *microglial integration in a synthetic microsystem*







EPA STAR Center Co-operative grant #835737, University of Wisconsin (W Murphy)

Incorporating the neurogenic domain (preliminary)





Neurovascular Unit-on-a-Chip Module





- Human endothelial cells, astrocytes, pericytes, and neurons.
- Microanalyzer for real time data (glucose, lactate, oxygen, pH, and 4 neurotransmitters).
- Testing neuroinflammation (LPS) and neurotoxicity (CPF) pathways.

EPA STAR grant (new), Vanderbilt University, D Cliffel and J Wikswo

Embryonic Human Neurovascular Unit (hNVU): quantitatively assess the


impact of chemical-induced disruption of neural morphogenesis and function.






- Impact of the endothelial-pericyte barrier on developmental neurotoxicity,
- Assess chemical effects on barrier function in a human cell-based *in vitro* system(s).

Qualification of barrier function in the hNVU



- Y-27632 is a cell permeable rock inhibitor that cross the NVU barrier increases proliferation and differentiation of human 'EZ neurosphere' cells to neural and astrocytic phenotypes (green fluorescence) in all models.
- BCH is a LAT-1 transporter inhibitor that does not cross the barrier; with BCH there are few NPCs cells, little differentiation (bright green neural structure) and almost no red astrocytes. In the MPS devices, proliferation and differentiation are similar to control cultures.

Embryo-fetal NVU Barrier: application to developmental neurotoxicity



- Microelectrode array (MEA) assay platform developed in Tim Shafer's lab.
- Monitors rat cortical neuronal network formation and electrochemical activity.
- Used to profile ToxCast chemicals for direct effects on neuronal networks.
- Rat cortical MEA system has been integrated with the transwell hNVU.

Summary

- NVU composed of multiple cells types and >400 genes, at least 90 of which play important roles in BBB development and function.
- BBB becomes functional soon after it forms during organogenesis (6-14 weeks in human gestation).
- Development and function is perturbed by multiple pathophysiological conditions and may underlie neurodevelopmental disorders linked to chemical exposure.
- Dynamics of the system modeled *in silico* and *in vivo* focusing on microglial sensing as potential roles in neurodevelopmental toxicity linked to their activation.

Acknowledgements





Nancy Baker (Leidos) Jessica Conley (CCTE) Florent Ginhoux (A*STAR Singapore) James Glazer (Indiana University) Sid Hunter (CCTE) Om Naphade (Brown University) Jocylin Pierro (CCTE) Kate Saili (now OAQP) Andrew Schwab (now Metabolon, Inc.) Aymeric Silvin (A*STAR Singapore) Richard Spencer (General Dynamics) Douglas Young (VTM Matrix Interface) Todd Zurlinden (now CPHEA)

EPA contract EP-D-13-056 Aruna Biomedical

Tracey Stice Steven Stice Forrest Goodfellow

EPA contract EP-D-13-053 VALA Sciences Lily Feng

EPA STAR Center Grant 835737 Univ Wisconsin

William Murphy, PI Bill Daly Eric Nguyen (now NIH/NEI) Gaurav Kaushik

EPA STAR Center Grant R839504 Vanderbilt Univ

David Cliffel, Pl John Wikswo

Selected References

- Knudsen TB, Klieforth, B and Slikker W Jr. (2017) Programming microphysiological systems for children's health protection. Exp Biol Med. 242: 1586-1592.
- Baker NC, Knudsen T and Williams A (2017) Abstract Sifter: a comprehensive front-end system to PubMed.
 F1000Research 2017, 6(Chem Inf Sci):2164 https://f1000research.com/articles/6-2164/v1
- Saili KS, Zurlinden TJ and Knudsen TB (2017) Modeling the neurovascular unit in vitro and in silico. Chapter for 'Handbook of Developmental Neurotoxicology', 2nd edition W Slikker, Jr (ed), Published by Elsevier, Inc. pp 127-142.
- Saili KS, Zurlinden TJ, Schwab A, Ginhoux F, Silvin A, Baker NC, Hunter ES III, Ginhoux F and Knudsen TB (2017) Blood-Brain Barrier Development: Systems Modeling and Predictive Toxicology. Birth Defects Res. 109: 1680-1710.
- Saili KS, Franzosa JA, Baker NC, Ellis-Hutchings RG, Settivari RS, Carney EW, Spencer R, Zurlinden TJ, Kleinstreuer NC, Li SZ, Xia M and Knudsen TB (2019) Systems modeling of developmental vascular toxicity. Curr Opin Toxicol 15: 55-63.
- Zurlinden TJ, Saili KS, Baker NC, Toimela T, Heinonen T and Knudsen TB (2020) A cross-platform approach to characterize and screen potential neurovascular unit toxicants. Reprod Toxl 96: 300-315.
- Schwab A et al., Development of complementary 3-dimensional human neurovascular unit models using static transwells and dual-compartment microfluidic devices. (In Revision).